Library

Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

1 June 2022. doid: 10.1111/bcp.15229

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

View publication

ALKS 7119 is a novel compound with in vitro affinity highest for the SERT, and for μ receptor, α -adrenoceptor, α -adrenoceptor, NMDA receptor and sigma non-opioid intracellular receptor 1. This first-in-human study evaluated safety and PK/PD effects of single ascending doses (SAD) of ALKS 7119 in healthy males and compared effects with neurotransmitter modulators with partially overlapping targets.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact